Potential use of drugs that target neural-immune pathways in the treatment of rheumatoid arthritis and other autoimmune diseases.
Many autoimmune disorders share two common features, dysregulation of the immune system and stress pathways. Two stress pathways, the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic nervous system (SNS), regulate immune system responses, through release of corticosteroids and norepinephrine (NE), respectively. These neuromediators act on immune cells via specific receptors on their surface to modulate the production of key regulatory cytokines. Glucocorticoids modulate immune responses by glucocorticoid binding to cytoplasmic glucocorticoid receptors within target cells. NE regulates immune responses through interaction with plasma membrane beta- or alpha-adrenergic receptors (AR). Both NE and glucocorticoids promote humoral immunity by altering macrophages and T cell cytokine production after an antigen challenge. Glucocorticoids and NE do this by inhibiting interleukin (IL)-12, and interferon (IFN)-gamma, which drives cell-mediated immunity. Additionally, catecholamines drive humoral immunity by stimulating macrophage IL-10 production. These catecholamine effects are mediated largely via beta(2)-AR activation. Both glucocorticoids and NE inhibit inflammation. However, under some circumstances NE promotes inflammation through interaction with macrophage alpha1-AR and subsequent increases in tumor necrosis factor alpha (TNFalpha production. Although macrophages do not normally express alpha(1)-AR, expression of this receptor on macrophages and monocytes occurs in some disease states, including rheumatoid arthritis (RA). Through these mechanisms the HPA axis and the SNS influence the course and progression of RA. Thus, the HPA axis and the SNS are likely to play key roles in the pathology of RA. Furthermore, therapeutic agents targeting the neural pathways that normally regulate immune system homeostasis may prove beneficial for treating RA and other autoimmune diseases.
Lorton
D
D
Hoover Arthritis Research Center, Sun Health Research Institute, Sun City, AZ 85351, USA. dianne.lorton@sunhealth.org
Lubahn
C
C
Bellinger
D L
DL
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D018663:Adrenergic Agents / Q000627:therapeutic use; D000818:Animals; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology; D005938:Glucocorticoids / Q000378:metabolism; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000276:immunology / Q000503:physiopathology; D008221:Lymphoid Tissue / Q000294:innervation; D008264:Macrophages / Q000187:drug effects / Q000276:immunology; D015213:Neuroimmunomodulation / Q000187:drug effects*; D011941:Receptors, Adrenergic / Q000187:drug effects; D013312:Stress, Physiological / Q000276:immunology / Q000503:physiopathology; D013564:Sympathetic Nervous System / Q000276:immunology / Q000503:physiopathology
D000276:Adjuvants, Immunologic; D000305:Adrenal Cortex Hormones; D018663:Adrenergic Agents; D005938:Glucocorticoids; D011941:Receptors, Adrenergic